Mark Chin

Managing Director, New York, US

Mark is an experienced venture capital investor, with significant experience as a board director of both private and public biotech companies in the US and Europe.

Mark sourced and led Arix investments into key portfolio companies, including: VelosBio (acquired by Merck for $2.75bn), Amplyx Pharmaceuticals (acquired by Pfizer), Aura Biosciences, Harpoon Therapeutics (Nasdaq IPO) and Imara (Nasdaq IPO). He is currently a Board Director of Harpoon Therapeutics, Inc. (Nasdaq: HARP), Imara Inc. (Nasdaq: IMRA) and Iterum Therapeutics plc (Nasdaq: ITRM).

Mark was previously a principal at Longitude Capital, where he focused on investments in biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, he worked in corporate development at Gilead Sciences and market planning at Genentech. He has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.